Should your patient be on extended-use OCs?

Contemporary Ob/Gyn

Volumn 48, Issue 9, 2003, Pages

  Sulak, Patricia L ^a  

^a Barr Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950086668     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Killick SR, ed. Contraception in Practice. London, UK: Martine Dunitz, 2000, Chapter 10.
2. Short RV. The evolution of human reproduction. Proc R Soc Lond B Biol Sci. 1976;195:3-24.
3. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: findings from the National Health Survey, 1984 to 1992. Am J Public Health. 1996;86:195-199.
4. Curtis KM, Hillis SO, Kieke BA Jr, et al. Visits toe mergency departments for gynecologic disorders in the United States, 1992-1994. Obstet Gynecol. 1998; 1:1007-1012.
5. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet. 2000; 355:922-924.
6. Geller SE, Harlow SD, Bernstein SJ. Differences in menstrual bleeding characteristics, functional status, and attitudes toward menstruation in three groups of women. J Womens Health Gend Based Med. 1999;8:533-540.
7. Kadir RA, Sabin CA, Pollard D, et al. Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia. 1998;4:836-841.
8. Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol. 2001;14:3-8.
9. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics. 1981;68:661-664.
10. Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. Am J Obstet Gynecol. 1978;130:833-847.
11. Teichmann A, Martens H, Bordasch C, et al. The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity. Eur J Contracept Reprod Health Care. 1996;1:245-256.
12. The ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16:1527-1535.
13. EA/NIH study shows women with endometriosis at greater risk for several other diseases. In the News. September 26, 2002. The Endometriosis Association Web site. Available at: http://endometriosisassn.org/inthe-news.html. Accessed March 31, 2003.
14. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemo-graphic factors. JAMA. 1992;267:64-69.
15. MacGregor EA. Menstruation, sex hormones, and migraine. Neurol Clin. 1997;15:125-141.
16. Epstein MT, Hockaday JM, Hockaday TD. Migraine and reproductive hormones throughout the menstrual cycle, Lancet. 1975;1;543-548.
17. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
18. Chabriat H, Danchot J, Michel P, et al. Precipitating factors of headache. A prospective study in a national control-matched survey in migraineurs and nonmi-graineurs. Headache. 1999;39:335-338.
19. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-266.
20. Whitty CW, Hockaday JM, Whitty MM. The effect of oral contraceptives on migraine. Lancet. 1966:1:856-859.
21. Cote I, Jacobs P, Cumming D. Work loss associated with increased menstrual loss in the United States. Obstet Gynecol. 2002;100:683-687.
22. Jones GL, Kennedy SH, Jenkinson C. Health-related quality of life measurement in women with common benign gynecologic conditions: a systematic review. Am J Obstet Gynecol. 2002;187:501-511.
23. Snider S. The Pill: 30 Years of Safety Concerns. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/bbs/topics/CONSUMER/ CON00027.html. Accessed March 31, 2003.
24. Contraception and Reproductive Health. Fast Stats A to Z. National Center for Health Statistics Web site. Available at: http://www.cdc.gov/nchs/ faststats/. Accessed March 31, 2003.
25. Peipert JF, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol. 1993;82:112-117.
26. Health Benefits of Oral Contraception Clinical Proceedings. March 1, 1999. Association of Reproductive Health Professionals (ARHP) Web site. Available at: http://www.arhp.org/heaIthcareproviders/onlinepublications/ clinicalproceedings/successful/occp/mar99a.cfm?ID=186. Accessed March 31, 2003.
27. Clark LR. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. J Pediatr Adolesc Gynecol. 2001;14:153-162.
28. Tessler SL, Peipert JF. Perceptions of contraceptive effectiveness and health effects of oral contraception. Womens Health Issues. 1997;7:400-406.
29. Dayal M, Bamhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med. 2001;19:295-303.
30. Larsson G, Milsom I, Lindstedt G, et al. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception. 1992:46:327-334.
31. Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol. 1998;77:13-19.
32. US Department of Health and Human Services, National Institutes of Health. Facts about Oral Contraceptives, http://www.nih.gov/health/chip/hichd/ oral-cnt/. Accessed April 25, 2002.
33. Medical Management of Endometriosis. ACOG Practice Bulletin No. 11. Washington, D.C.: American College of Obstetricians and Gynecologists, December 1999.
34. Ruchhoft EA, Elkind-Hirsch KE, Malinak R. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with 'continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist. Fertil Steril. 1996;66:54-60.
35. Murray SC, Muse KN. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy. Fertil Steril. 1997;67:390-393.
36. Guidance for Industry. Combined Oral Contraceptives-Labeling for Healthcare Providers and Patients. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). June 2000. Available at: http://www.fda.gov/cder/guidance/2448dft.pdf. Accessed March 31, 2003.
37. Sulak PJ, Kuehl TJ, Ortiz M, et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142-1149.
38. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179-183.